J J Sevigny

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial
    J J Sevigny
    Merck Research Laboratories, North Wales, PA 19454, USA
    Neurology 71:1702-8. 2008

Detail Information

Publications1

  1. ncbi Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial
    J J Sevigny
    Merck Research Laboratories, North Wales, PA 19454, USA
    Neurology 71:1702-8. 2008
    ..We examined whether the growth hormone secretagogue MK-677 (ibutamoren mesylate), a potent inducer of IGF-1 secretion, slows the rate of progression of symptoms in patients with AD...